With Trump in the U.K., GSK touts $30 billion investment in U.S. over 5 years

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.

LONDON — The U.K.-based drugmaker GSK said early Wednesday that it planned to invest $30 billion in the U.S. over five years, an announcement timed to this week’s state visit here by President Trump.

The company, which said the funds would be used to expand research and manufacturing operations and build out AI capabilities, is the latest drugmaker to unveil major investments in the U.S. since the start of the Trump administration, following the likes of Eli Lilly, AstraZeneca, Novartis, and others. 

The U.S. is the largest market for drugmakers, and the industry had been shifting more resources there even before Trump took office again. But the headline-grabbing sums have also allowed companies, under threat of tariffs on pharmaceutical products and of Trump’s proposed drug pricing plan, to appeal to the administration. On tariffs specifically, companies have argued they already make some drugs for U.S. patients in the U.S. — and also have committed to building up manufacturing there even further.